Creatine, the popular workout supplement, may have a surprising second act: boosting the immune system's ability to fight cancer. A new UCLA study found that creatine energizes dendritic cells — the immune system's "commanders" that activate cancer-killing T cells — slowing tumor growth in mouse models. Human trials are still needed, but the findings could point toward a simple way to make immunotherapy work for more patients.
Creatine, the popular workout supplement, may have a surprising second act: boosting the immune system's ability to fight cancer.
A new UCLA study published in iScience found that creatine plays a key role in powering dendritic cells — the immune system's "commanders" that detect tumors and activate cancer-killing T cells. When researchers engineered dendritic cells that couldn't absorb creatine, those cells survived less effectively, became less active, and were far worse at priming T cells to attack tumors. On the flip side, daily creatine injections in mouse melanoma models significantly slowed tumor growth and boosted both the number and activity of tumor-infiltrating dendritic cells.
The mechanism? Creatine increases ATP (cellular energy) levels inside dendritic cells, essentially acting like a rechargeable battery that keeps immune cells powered up even as they compete with fast-growing tumor cells for nutrients. Lab experiments also showed creatine enhanced human dendritic cells used in cancer vaccines, improving their ability to stimulate anti-tumor T cell responses.
Key Takeaways:
Why it matters: If clinical trials confirm these findings, creatine — already widely used and considered safe at recommended doses — could become a low-cost, accessible tool to make existing cancer immunotherapies more effective for a broader range of patients.
